In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Alpine Immune Sciences Inc (ALPN), with a price target of $13. The company’s shares closed on Friday at $4.80, close to its 52-week low of $4.51.
Breidenbach wrote:
“At the 2018 ASH meeting, Alpine showcased the versatility of its vIgD (variant immunoglobulin domain) technology platform with three preclinical presentations. These included an oral presentation describing the role of ICOS in acute graft- versus-host disease (GVHD) and showing that dual blockade of ICOS and CD28 with ALPN-101 could be an effective therapeutic strategy. In early 2019, ALPN-101 could enter the clinic, starting with an Australian healthy-volunteer study that could expand to include patients with rare autoimmune disorders including steroid refractory GVHD and hemophagocytic lymphohistiocytosis (HLH). In a poster presentation, Alpine unveiled a new product class dubbed “switch TIPs” which could be broadly deployed to improve the efficacy of adoptive cell therapies. Outperform, $13 PT.”
According to TipRanks.com, Breidenbach is a 1-star analyst with an average return of -2.1% and a 32.3% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Sorrento Therapeutics, and Seres Therapeutics.
Currently, the analyst consensus on Alpine Immune Sciences Inc is a Moderate Buy with an average price target of $12.50, implying a 160.4% upside from current levels. In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $12 price target.
.
See today’s analyst top recommended stocks >>
Based on Alpine Immune Sciences Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.14 million. In comparison, last year the company had a net profit of $2.12 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program.
